Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type diabetes.

被引：0
|
作者：
He, YL [1 ]
Balch, A [1 ]
Campestrini, J [1 ]
Rivere, GJ [1 ]
Serra, D [1 ]
Prasad, P [1 ]
Ligueros-Saylan, M [1 ]
机构：
[1] Novartis Pharmaceut, NIBR, Cambridge, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2005年 / 77卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P56 / P56
页数：1
相关论文
共 50 条
  • [31] Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
    Ahrén, B
    Gomis, R
    Standl, E
    Mills, D
    Schweizer, A
    DIABETES CARE, 2004, 27 (12) : 2874 - 2880
  • [32] Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
    Abd A. Tahrani
    Milan K. Piya
    Anthony H. Barnett
    Advances in Therapy, 2009, 26 : 249 - 262
  • [33] Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes
    Gallwitz, Baptist
    DRUGS OF TODAY, 2007, 43 (01) : 13 - 25
  • [34] Sitagliptin phosphate: A DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
    Zerilli, Tina
    Pyon, Eunice Y.
    CLINICAL THERAPEUTICS, 2007, 29 (12) : 2614 - 2634
  • [35] Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
    Shubrook, Jay
    Colucci, Randall
    Guo, Aili
    Schwartz, Frank
    CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2011, 4 : 1 - 12
  • [36] Linagliptin: A New DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
    Toth, Peter P.
    POSTGRADUATE MEDICINE, 2011, 123 (04) : 46 - 53
  • [37] DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
    Deacon, Carolyn F.
    Carr, Richard D.
    Holst, Jens J.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 : 1780 - 1794
  • [38] Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
    Tahrani, Abd A.
    Piya, Milan K.
    Barnett, Anthony H.
    ADVANCES IN THERAPY, 2009, 26 (03) : 249 - 262
  • [39] EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR IN HEMODIALYSIS PATIENTS WITH TYPE 2 DIABETES
    Abe, Masanori
    Okada, Kazuyoshi
    Oikawa, Osamu
    Maruyama, Noriaki
    Furukawa, Tetsuya
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 216 - 216
  • [40] Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials
    Karasik, Avraham
    Aschner, Pablo
    Katzeff, Harvey
    Davies, Michael J.
    Stein, Peter P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (02) : 489 - 496
12345